Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...

Officers with the Urbana Police Department are actively responding to a multi-vehicle crash near the intersection of Philo ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancer Recently announced positive ...

Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...

CSPC PHARMA (01093.HK) announced that JMT108, a new Class I bi-functional fusion protein drug developed by the group, has ...

Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive ...